Trial Search Results

Pharmacokinetics of Daunorubicin in Young Patients With Cancer

This laboratory study is looking at the pharmacokinetics of daunorubicin in young patients with cancer. Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about how patients respond to treatment with certain chemotherapy drugs.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Children's Oncology Group

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Other: pharmacological study
  • Procedure: dual x-ray absorptimetry

Phase:

N/A

Eligibility


DISEASE CHARACTERISTICS:

   - Diagnosis of any malignancy

   - Must be receiving a chemotherapy regimen that includes daunorubicin hydrochloride
   administered as an infusion of any duration for < 24 hours on either a 1- or a 2-day
   schedule, including bolus and all short infusion schedules

PATIENT CHARACTERISTICS:

   - Not pregnant or nursing

   - No significant uncontrolled systemic illness

   - Large implanted prostheses allowed (should not undergo dual energy x-ray
   absorptiometry scan)

PRIOR CONCURRENT THERAPY:

   - See Disease Characteristics

Ages Eligible for Study

N/A - 21 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs
650-723-5535
Not Recruiting